Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 3, 1996, Pages

  Shimada, Y ^a   Rougier, P ^b   Pitot, H ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

colorectal cancer; CPT 11; phase II

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ALOPECIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0029973982     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00292-4     Document Type: Article

References (27)

1. Hsiang YH, Lihou MG, Liu F. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49, 5077-5082.
2. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994, 86, 836-842.
3. Giovanella BC, Stehlin JS, Wall ME, et al. DNA-topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246, 1046-1048.
4. Shimada Y, Rothenberg M, Hilsenbeck SG, et al. Activity of CPT-11 (irinotecan hydrochloride) : a topoisomerase inhibitor against human tumor colony-forming units. Anticancer Drugs 1994, 5, 202-206.
5. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumour effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988, 21, 71-74.
6. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990, 17, 115-120.
7. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83, 1164-1168.
8. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992, 84, 972-974.
9. Rothenberg ML, Kuhn JG, Burris HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11, 2194-2204.
10. De Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54, 4347-4354.
11. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994, 54, 427-436.
12. Abigerges D, Chabot GG, Armand J, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13, 210-221.
13. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995, 6, 133-140.
14. Armand J-P. CPT-11: clinical experience in phase I studies. Semin Oncol, 1996, 23, 27-33.
15. Rougier P, Culine S, Bugat R, et al. A phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with 5-FU-based chemotherapy. J Clin Oncol, in press.
16. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11, 909-913.
17. Pitot HC, Wender D, O'Connell MJ, et al. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 1994, 13, 197 (abstract 573).
18. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992, 10, 904-911.
19. Scheithauer W, Rosen H, Kornek G, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-755.
20. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
21. Cohen AM, Minsky BD, Schilsky RL. Colon Cancer. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th edition. Philadelphia, JB Lippincott, 1993, 929-977.
22. Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988, 6, 469-475.
23. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma, a prospective randomized phase III trial. J Clin Oncol 1989, 7, 1419-1426.
24. Adenis A. Les tumeurs gastro-intestinales. Compte-endus ASCO-AACR 1993. Bull Cancer 1993, 8, 65S-72S.
25. Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second line therapy for PTS with 5-FU-refractory colorectal cancer. 30th Annual Meeting of the American Society of Clinical Oncology, 14-17 May, 1994. Dallas, Texas (abstract 578).
26. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996, 32A(Suppl. 3), S18-S23.
27. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxy camptothecin. Cancer Res 1993, 53, 2823-2829.